PET agent targeting kidney masses earns FDA's breakthrough and fast-track designations
A new PET imaging agent that helps differentiate varying types of kidney masses was just awarded the U.S. Food and Drug Administration’s breakthrough therapy and fast-track designations.
China-based Norroy Bioscience, which specializes in developing diagnostic and therapeutic radiopharmaceuticals, announced the recent regulatory wins on Wednesday. Norroy’s 68Ga-NYM096 is designed to help characterize indeterminate renal masses and distinguish clear cell renal cell carcinoma (ccRCC) from other kidney lesions; it works by targeting carbonic anhydrase IX (CAIX), a protein highly expressed in ccRCC.
It is estimated that clear cell disease accounts for approximately 70% to 80% of renal cell carcinoma cases. The company said the agent is being developed as a noninvasive imaging option for patients whose renal masses have been identified on CT or MRI but remain difficult to characterize. The designations come as researchers and clinicians seek alternatives to the current management of indeterminate renal masses.
Preliminary clinical data for 68Ga-NYM096 have shown promise in terms of safety and efficacy, and additional detailed findings are expected to be presented at the 2026 EANM Annual Congress. The company plans to initiate Phase 1 clinical trials in both China and the U.S. soon.
"We have seen promising clinical data from the ongoing development of 68Ga-NYM096, supporting its potential to advance the diagnosis and management of patients with ccRCC,” Norroy Founder and CEO Peng Fang said in an announcement. “We believe this innovative imaging agent has the potential to reshape the diagnosis and management of ccRCC and ultimately benefit more patients worldwide."
The FDA's Fast Track program is intended to assist in the development and expedite regulatory review for products capable of addressing serious conditions with unmet medical needs.
Learn more here.
In addition to her background in journalism, Hannah also has patient-facing experience in clinical settings, having spent more than 12 years working as a registered rad tech. She began covering the medical imaging industry for Innovate Healthcare in 2021.